Recurrent Ovarian Cancer


Goodbye Brain Fog! Strategies to Help Get Your Thinking Back on Track (March 22, 2017)

Have a Question about Cancer-Related Brain Fog? Ask the Expert! Live Web Chat Tuesday, March 28th, 4:00-5:00 PM, EST Tune in here. Join us for a live Ask the Expert session with neurocognitive expert Heather... Continue Reading

Lynparza™ Clinical Trial Demonstrates Survival Benefit in Relapsed Ovarian Cancer (November 9, 2016)

AstraZeneca has announced positive results from the Phase III SOLO-2 trial designed to determine the efficacy of LynparzaTM (olaparib) oral therapy for the maintenance treatment of platinum-sensitive relapsed,... Continue Reading

Update on PARP Inhibitors for Ovarian Cancer with BRCA Mutations (October 31, 2016)

Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more than 15,000 die of the disease. Treatment for ovarian cancer commonly involves surgery and/or chemotherapy.... Continue Reading

Tesaro Provides Real Benefit to Ovarian Cancer Patients (October 20, 2016)

Patients with platinum-sensitive recurrent ovarian cancer showed significantly improved cancer-free survival with Tesaro (niraparib) in the first clinical trial directly comparing a poly(ADP)-ribose polymerase... Continue Reading

National Ovarian Cancer Coalition Launches CancerConnect Social Media Platform for Women with Ovarian Cancer (September 26, 2016)

Austin TX/Sun Valley ID–The National Ovarian Cancer Coalition (NOCC) now offers a specialized social network for women with ovarian cancer. The NOCC CancerConnect Community offers these women a safe,... Continue Reading

Niraparib Improves Progression-Free Survival in Ovarian Cancer (July 13, 2016)

The PARP inhibitor niraparib improves the time to cancer progression among patients with recurrent ovarian cancer when used as maintenance therapy during platinum-based chemotherapy. Each year in the United... Continue Reading

Ovarian Cancer Awareness: Risk, Prevention, Treatment, Survivorship, & Community (September 2, 2015)

As the month of September brings ovarian cancer into focus, it’s time to increase public understanding of the disease, including its prevalence, approaches to screening and prevention, treatment options,... Continue Reading

Drug Rucaparib Promising in Pretreated BRCA-Positive Ovarian Cancer (June 15, 2015)

The drug rucaparib appears active in women with recurrent BRCA-positive ovarian cancer that has progressed after previous treatment. These findings were presented at 2015 Annual Meeting of the American... Continue Reading

Combination of Avastin®, Taxol®, and Carboplatin Improves Survival in Recurrent Platinum-Sensitive Ovarian Cancer (April 29, 2015)

The addition of Avastin® (bevacizumab) to Taxol® (paclitaxel) and carboplatin for the treatment of recurrent platinum-sensitive ovarian cancer appears to improve survival. These findings were presented... Continue Reading

Lynparza Approved in Advanced Ovarian Cancer (December 29, 2014)

CancerConnect News: The U.S. Food and Drug Administration has granted accelerated approval to LynparzaTM (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective... Continue Reading

Avastin Approved by the FDA for Recurrent Ovarian Cancer (December 2, 2014)

The FDA approval was based on the results of the AURELIA clinical trial, which involved 361 women with ovarian cancer that had recurred less than 6 months after their most recent platinum-based chemotherapy... Continue Reading

AFCR Scientists Uncovered Potential New Treatment for Ovarian Cancer (November 11, 2014)

(CancerConnect) A potential new treatment for ovarian cancer – the most lethal cancer of the female reproductive system – has recently been uncovered, thanks to research supported in part by the... Continue Reading

Adding Cediranib to Olaparib Markedly Improves Progression-Free Survival but Increases Toxicity in Recurrent Platinum-Sensitive Ovarian Cancer (October 21, 2014)

The addition of the antiangiogenic agent cediranib to the PARP inhibitor olaparib in women with recurrent platinum-sensitive ovarian cancer improves time to cancer progression and survival. The results... Continue Reading

Ovarian Cancer Talk: Participate in a Live Video Chat With the Experts from Roswell Park Cancer Institute (September 22, 2014)

Straight from Roswell Park Cancer Institute in Buffalo, N.Y., to your computer or mobile device, four leading experts in ovarian cancer will broadcast a live, interactive video chat from 6 to 7 p.m. on... Continue Reading

National Gynecologic Cancer Awareness Month on CancerConnect (September 9, 2014)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of cervical, ovarian and uterine cancer educational programs for national gynecologic cancer awareness month.... Continue Reading

National Ovarian Cancer Awareness Month on CancerConnect (September 2, 2014)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of ovarian cancer educational programs for national ovarian cancer awareness month. As the month of September brings... Continue Reading

Avastin Plus Chemotherapy Improves Progression-Free Survival in Platinum-Resistant Recurrent Ovarian Cancer (April 9, 2014)

The addition of Avastin® (bevacizumab) to standard chemotherapy significantly improved progression-free survival and objective response rate among women with platinum-resistant recurrent ovarian cancer,... Continue Reading

Aspirin as Ovarian Cancer Prevention? Research Says Maybe (February 20, 2014)

New evidence suggests that an aspirin a day may reduce the risk of ovarian cancer. But more research is needed before your doctor will routinely prescribe it for prevention. You may know that low doses... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS